Skip to main content

Pfizer acquires Basel-based Therachon

| News

Pfizer acquires Basel-based Therachon

09.05.2019

U.S. pharmaceutical company Pfizer is acquiring Basel biotech Therachon for US$ 340 million. Additional payments of US$ 470 million may also be received on the achievement of key milestones. Therachon has developed a drug for the treatment of a form of short-limbed dwarfism.

Drug discovery (img: motorolka_10/shutterstock)

Therachon Holding AG has developed products for the treatment of achondroplasia and short bowel syndrome. These include product candidate TA-46 for the treatment of achondroplasia, “a genetic condition and the most common form of short-limbed dwarfism”, as was reported in a press release from Pfizer. The U.S. pharmaceutical company is acquiring Basel-based Therachon for US$ 340 million and has also committed itself to an additional US$ 470 million in payments contingent on the achievement of key milestones in the development and commercialization of TA-46. Prior to the closing of the transaction, Therachon will “spin-off its apraglutide development program into a separate, independent company”. This program for short bowel syndrome is currently in Phase 2 development. Pfizer will be involved in this company via Pfizer Ventures.

“At Pfizer, our strategy is focused on advancing the most promising science in the world, regardless of whether it is found inside or outside of our labs,” commented Mikael Dolsten, Chief Scientific Officer and President of Worldwide Research, Development and Medical at Pfizer. “By acquiring Therachon, we hope to leverage Pfizer’s leading scientific and development capabilities to more rapidly advance this potentially promising therapy for people with achondroplasia.”

Achondroplasia currently affects approximately 250,000 people worldwide and there are currently no approved treatments. TA-46 developed by Therachon has completed clinical phase 1 and received Orphan Drug Designation from the European Medicines Agency and the U.S. Food and Drug Administration. “Therachon is a great example of the value that can be built from cutting edge European science,” said Tom Woiwode, Chairman and Managing Director of Versant Ventures, one of the founding investors in Therachon. Luca Santarelli, CEO of Therachon, adds: “We look forward to Pfizer continuing to develop TA-46 in the hope that it will significantly improve the lives of children suffering from achondroplasia.”

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Building the future of healthtech, digital health and techbio in the Basel Area

Meet our Chief Representative USA: with over 30 years in the biotech industry, Kirsten Detrick brings invaluable expertise for companies...
Read More

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Do you have a question? We'd like to hear from you.